KR20230131815A - 에토포시드 토니리베이트 제제 - Google Patents

에토포시드 토니리베이트 제제 Download PDF

Info

Publication number
KR20230131815A
KR20230131815A KR1020237009044A KR20237009044A KR20230131815A KR 20230131815 A KR20230131815 A KR 20230131815A KR 1020237009044 A KR1020237009044 A KR 1020237009044A KR 20237009044 A KR20237009044 A KR 20237009044A KR 20230131815 A KR20230131815 A KR 20230131815A
Authority
KR
South Korea
Prior art keywords
liquid pharmaceutical
etoposide
infusion solution
polysorbate
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237009044A
Other languages
English (en)
Korean (ko)
Inventor
다비데 구찌
바즈케즈 안나 몬테스
루비오 하비에르 마티네즈
루디 토마
Original Assignee
셀액트 파마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2012954.0A external-priority patent/GB202012954D0/en
Priority claimed from GBGB2012956.5A external-priority patent/GB202012956D0/en
Application filed by 셀액트 파마 게엠베하 filed Critical 셀액트 파마 게엠베하
Publication of KR20230131815A publication Critical patent/KR20230131815A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237009044A 2020-08-19 2021-08-19 에토포시드 토니리베이트 제제 Pending KR20230131815A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2012954.0A GB202012954D0 (en) 2020-08-19 2020-08-19 Etoposide toniribate formulation
GBGB2012956.5A GB202012956D0 (en) 2020-08-19 2020-08-19 Etoposide toniribate formulation
GB2012954.0 2020-08-19
GB2012956.5 2020-08-19
PCT/EP2021/073034 WO2022038226A1 (en) 2020-08-19 2021-08-19 Etoposide toniribate formulation

Publications (1)

Publication Number Publication Date
KR20230131815A true KR20230131815A (ko) 2023-09-14

Family

ID=80322580

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237009044A Pending KR20230131815A (ko) 2020-08-19 2021-08-19 에토포시드 토니리베이트 제제

Country Status (7)

Country Link
US (1) US20230398069A1 (cg-RX-API-DMAC7.html)
EP (1) EP4199933A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023539154A (cg-RX-API-DMAC7.html)
KR (1) KR20230131815A (cg-RX-API-DMAC7.html)
AU (1) AU2021327164A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189720A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038226A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4233837A1 (en) * 2022-02-24 2023-08-30 CellAct Pharma GmbH Solid and oral etoposide toniribate compositions
CN116983259A (zh) * 2023-09-27 2023-11-03 成都瑞尔医药科技有限公司 一种依托泊苷注射液的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69431071T2 (de) * 1993-12-29 2003-03-20 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
ES2354065T3 (es) * 2001-12-03 2011-03-09 Universitätsklinikum Charité Der Humboldt- Universität Zu Berlin Podofilotoxinas en calidad de agentes antiproliferativos.
JP4020256B2 (ja) * 2003-05-23 2007-12-12 日本化薬株式会社 前立腺癌の局所治療剤
EP2308467A3 (en) * 2005-06-17 2011-06-22 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
US9889147B2 (en) * 2010-04-16 2018-02-13 Cellact Pharma Gmbh Analogues of etoposide for the treatment of tumours
LT3228319T (lt) * 2011-04-28 2020-09-25 Oncopeptides Ab Liofilizuotas citotoksinių dipeptidų preparatas
SI3228319T1 (sl) * 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
GB2513299A (en) * 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells

Also Published As

Publication number Publication date
US20230398069A1 (en) 2023-12-14
WO2022038226A1 (en) 2022-02-24
AU2021327164A1 (en) 2023-03-16
EP4199933A1 (en) 2023-06-28
CA3189720A1 (en) 2022-02-24
JP2023539154A (ja) 2023-09-13

Similar Documents

Publication Publication Date Title
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
CN102781447B (zh) 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液
KR20080030024A (ko) 도세탁셀의 약제학적 액상제제
JP5334937B2 (ja) ビノレルビンを含むソフトカプセルのための経口製薬組成物及び治療方法
JP6356873B2 (ja) タキサン系活性成分含有液体組成物及び液体製剤
WO2022038226A1 (en) Etoposide toniribate formulation
CN116350619B (zh) 一种口服紫杉烷类药物组合物
CN115990262B (zh) 不含乙醇和磷脂的湿热灭菌的尼莫地平组合物及其制备方法
EP4483871A1 (en) Taxotere composition and method
US7658943B2 (en) Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
CN103816126B (zh) 一种含有丁溴东莨菪碱的药物组合物
WO2009043226A1 (en) A stable liquid composition comprising taxan derivatives and its preparation method.
US20160120742A1 (en) Compositions including cabazitaxel
RU2279873C2 (ru) Пероральная фармацевтическая композиция для мягких капсул, содержащая винорелбин, и способ лечения
WO2023161452A1 (en) Solid and oral etoposide toniribate compositions
HK40109413A (en) Plinabulin micelle composition and preparation method thereof
JP2025533271A (ja) プリナブリンミセル組成物及びその調製方法
CN107080748A (zh) 一种阿魏酸川芎嗪固体脂质纳米粒及其制备方法与应用
HK40120962A (en) Taxotere composition and method
CN111557934A (zh) 一种含多西他赛的药物组合物及其制备方法和用途
HK1112672A1 (en) Vinorelbine soft capsule, preparing method and use thereof
HK1112672B (en) Vinorelbine soft capsule, preparing method and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230315

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240819

Comment text: Request for Examination of Application